Bristol Myers Squibb’s experimental autoimmune disease drug deucravacitinib helped treat moderate-to-severe lupus in a Phase 2 trial. Results were recently presented at a medical conference in Denmark, showing two doses of the pill led to significantly higher response rates than did a placebo.

Company executives said they will advance deucravacitinib into Phase 3 trials in lupus, adding a new opportunity for a drug that’s already under Food and Drug Administration review for psoriasis and is in Phase 3 testing for psoriatic arthritis. The drug didn’t help patients with ulcerative colitis in a mid-stage trial, however.

Deucravacitinib is one of nine new drugs that Bristol Myers executives believe will help offset revenue losses expected to follow looming patent expirations for top-selling drugs like blood thinner Eliquis and cancer immunotherapy Opdivo. The company estimates deucravacitinib could earn as much as $4 billion a year by 2029.